About this item:

239 Views | 187 Downloads

Author Notes:

Michael J. Eckrich, MD, MPH, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.Telephone: 414-805-0700; Fax: 414-805-0714. meckrich@carolinashealthcare.org

M.J.E., M.E. designed the research study; M.J.E., K.W.A. and M.E. performed the research; R.C., P.C., K.G., J.H., D.M., H.J.D analyzed the data; and M.J.E and M.E. wrote the paper.

Subject:

Research Funding:

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • UNRELATED DONOR TRANSPLANTATION
  • MATCHED SIBLING DONORS
  • VERSUS-HOST-DISEASE
  • BONE-MARROW
  • PERIPHERAL-BLOOD
  • IMMUNOSUPPRESSIVE THERAPY
  • GRAFT
  • GVHD
  • PATHOPHYSIOLOGY
  • SURVIVAL

Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia

Tools:

Journal Title:

American Journal of Hematology

Volume:

Volume 89, Number 2

Publisher:

, Pages 125-129

Type of Work:

Article | Post-print: After Peer Review

Abstract:

We compared outcomes after hematopoietic cell transplantation in patients of African American (n=84) and Caucasian (n=215) descent with severe aplastic anemia. African Americans and Caucasians were matched for age, donor-recipient human leukocyte antigen match, graft type, and transplantation year. The median follow-up of surviving patients was 5 years. In multivariate analysis, overall mortality risks were higher for African Americans compared to Caucasians (relative risk 1.73, P=0.01). The 5-year probabilities of overall survival adjusted for interval from diagnosis to transplantation, and performance score was 58% for African Americans and 73% for Caucasians. The day-100 cumulative incidence of grade III-IV, but not grade II-IV acute graft-versus-host disease (GVHD), was higher in African Americans compared to Caucasians (29% vs. 13%, P=0.006). Although the 5-year cumulative incidence of chronic GVHD was not significantly different between the racial groups, African Americans were more likely to have extensive chronic GVHD compared to Caucasians (72% vs. 49%, P=0.06). Survival differences between Caucasians and African Americans can be attributed to multiple factors. Our data suggest that some of the observed survival differences between Caucasians and African Americans may be explained by higher rates of acute GVHD and severity of chronic GVHD.

Copyright information:

© 2013 Wiley Periodicals, Inc.

Export to EndNote